ISSN: 2459 - 1777 | E-ISSN 2587-0394

Quick Search




Intravitreal Ranibizumab Therapy for Choroidal Neovascularization Secondary to Pathological Myopia: 3 Year Outcome [Beyoglu Eye J]
Beyoglu Eye J. 2018; 3(1): 8-12 | DOI: 10.14744/bej.2018.88598

Intravitreal Ranibizumab Therapy for Choroidal Neovascularization Secondary to Pathological Myopia: 3 Year Outcome

İrfan Perente1, Özgür Artunay1, Alper Şengül2
1Department of Ophthalmology, Beyoglu Eye Training And Research Hospital, Istanbul, Turkey
2Department of Ophthalmology, T.C. Istanbul Bilim University Medical Faculty, Istanbul, Turkey

INTRODUCTION: The purpose of this study is to report our functional and anatomical results of intravitreal ranibizumab (IVR) for choroidal neovascularization secondary to pathological myopia (mCNV).
METHODS: In this retrospective study, 32 mCNV patients’ 32 eyes were evaluated. After one IVR injection patients were followed by an as-needed monthly regime. Best-corrected visual acuity (BCVA) and optic coherence tomography (OCT) findings were evaluated at baseline and then monthly. Re-injection criteria were; reduction in visual acuity and/or increase in central macular thickness measured with OCT.
RESULTS: The mean age of the subjects was 57.7±14.6 years, and the mean axial length was 27.8±1.3 mm. Mean visual acuity improved significantly from 46.4±9.7 letters at baseline to 54.1±9.5 letters at last follow-up visit (p<0.05). The mean central macular thickness decreased from 301.4±11.7 μm at baseline to 258.8 ±12.5 μm at the last visit (p>0.05). The average number of injections was 3.5±1,1, 2.3±0.9 and 1.7±0.8 injections at 12, 24 and 36 months respectively.
DISCUSSION AND CONCLUSION: This study has shown that IVR injections provide a significant long-term visual and anatomical benefit in mCNV with a small number of injections.

Keywords: Central macular thickness, intravitreal ranibizumab, myopic choroidal neovascularization.

İrfan Perente, Özgür Artunay, Alper Şengül. Intravitreal Ranibizumab Therapy for Choroidal Neovascularization Secondary to Pathological Myopia: 3 Year Outcome. Beyoglu Eye J. 2018; 3(1): 8-12

Corresponding Author: Alper Şengül, Türkiye
LookUs & Online Makale